Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Regeneron and Roche have inked a global collaboration on the COVID-19 antibody cocktail REGN-COV2, with Roche taking ex-US rights and adding manufacturing…
Roche and Regeneron have agreed to jointly develop, manufacture and distribute Regeneron's anti-SARS-CoV-2 antibody cocktail REGN-COV2 worldwide. Each company…
The U.S. Food and Drug Administration today issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy casirivimab and…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Roche and Regeneron announced a global collaboration to develop, manufacture and distribute REGN-COV2 (casirivimab + imdevimab) for COVID-19. Capacity to expand 3.5x; Regeneron led US distribution while Roche handled ex-US. Each company committed dedicated manufacturing capacity annually; jointly funded ongoing Phase 3 prevention and Phase 1 safety studies. Financial split not disclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Regeneron Pharmaceuticals, Inc. (this deal) | 2020 | — | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2020 deals · Roche Holding AG deals · Infectious Disease deals